Bellerophon Therapeutics, Inc. (BLPH)

NASDAQ: BLPH · IEX Real-Time Price · USD
1.11
-0.03 (-2.63%)
At close: Sep 28, 2022 4:00 PM
1.07
-0.04 (-3.60%)
After-hours: Sep 28, 2022 4:18 PM EDT
-2.63%
Market Cap 10.60M
Revenue (ttm) n/a
Net Income (ttm) -18.65M
Shares Out 9.55M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,087
Open 1.21
Previous Close 1.14
Day's Range 1.07 - 1.24
52-Week Range 0.67 - 4.49
Beta -0.08
Analysts Buy
Price Target 24.99 (+2,151.4%)
Earnings Date Nov 14, 2022

About BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hy... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Feb 13, 2015
CEO Fabian Tenenbaum
Employees 20
Stock Exchange NASDAQ
Ticker Symbol BLPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BLPH stock is "Buy." The 12-month stock price forecast is 24.99, which is an increase of 2,151.35% from the latest price.

Price Target
$24.99
(2,151.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size

Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

8 hours ago - Zacks Investment Research

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibroti...

WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

1 day ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 month ago - GlobeNewsWire

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

4 months ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

4 months ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

5 months ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

8 months ago - GlobeNewsWire

Bellerophon Stock Surges After Positive Data From Sarcoidosis-Associated Pulmonary Hypertension Trial

Bellerophon Therapeutics Inc (NASDAQ: BLPH) shares are trading higher after topline data from Phase 2 study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse via right heart catheter...

9 months ago - Benzinga

Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pul...

Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial

9 months ago - GlobeNewsWire

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings e...

9 months ago - Zacks Investment Research

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

10 months ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

1 year ago - GlobeNewsWire

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

Other symbols: ENTX
1 year ago - Benzinga

Bellerophon to Present at the Jefferies Virtual Healthcare Conference

WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

1 year ago - GlobeNewsWire

Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since 2...

1 year ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

1 year ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

1 year ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treat...

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatmen...

WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference

WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates

Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

1 year ago - Zacks Investment Research

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results

WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial ...

WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon to Present at Two September Investor Conferences

WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...

2 years ago - GlobeNewsWire